Here’s what you should know:
1. Vosevi is a fixed-dose, combination tablet which consists of sofosbuvir, velpatasvir and voxilaprevir. All three drugs are FDA approved.
2. According to a release, this is the first treatment for patients who previously used a direct-acting antiviral for HCV.
3. Vosevi is an option for patients who did not have success with a direct-acting agent.
4. Gilead’s President and CEO John Milligan said in a release, “The evolution of Gilead’s portfolio of HCV single-tablet regimens has been driven by our commitment to address previously unmet needs and put the possibility of cure within reach for as many HCV patient populations as possible.”
http://www.gilead.com/news/press-releases/2017/7/us-food-and-drug-administration-approves-gileads-vosevi-sofosbuvirvelpatasvirvoxilaprevir-for-retreatment-of-adults-with-chronic-hepatitis-c-virus
More articles on gastroenterology:
GI center to know: Spokane Digestive Disease Center
Solutions for every setting — Gastroenterologist Dr. Michael DiMarino on the gMed™ suite
GI leader to know: Dr. Paul Craig of Valley Gastroenterology
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
